Skip to content

HIFU for prostate cancer

How ultrasound heats and destroys the tumor, focal, whole-gland or after radiotherapy, with the results and the limits.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 18, 2026
Book a consultation
Drawing of the pelvis seen from the side, with the bladder, the prostate and the rectum, and the HIFU probe inside the rectum, covered by a water balloon, sending an ultrasound beam that converges on the tumor inside the prostate, surrounded by the heated area
On this page

Quick answer

HIFU, high-intensity focused ultrasound, destroys prostate cancer with heat: a probe in the rectum focuses ultrasound waves on one point of the gland and heats the tissue above 65 °C.1 It can treat only the area of the tumor, half of the prostate or the whole gland, as a first treatment or when the cancer comes back after radiotherapy.7,9,10,14 The 2026 European guideline recommends offering it, for intermediate-risk disease, only within clinical trials or registries, and not offering it for high-risk disease.1 The American guideline includes HIFU among the salvage options after radiotherapy.3

What HIFU is

HIFU stands for high-intensity focused ultrasound. The ultrasound used in scans passes through the body without causing damage. In HIFU, the waves leave a curved face of the probe and converge on a small point, much like a magnifying glass focuses sunlight. At that point the temperature rises above 65 °C, and the cells die from the heat.1

HIFU is one of the focal therapies, alongside cryotherapy, irreversible electroporation, photodynamic therapy and focal laser ablation.

How it is done

In the studies, HIFU is done like this:

  • Through the rectum: the probe goes into the rectum, covered by a sheath with circulating chilled water. It shows the prostate on ultrasound and delivers the energy to the planned points.1,5
  • Under anesthesia: the treatment is done with the patient anesthetized. In the 2012 UK study, a catheter to drain the urine was placed through the lower abdomen, above the pubic bone, under the same anesthetic, and removed after a median of 8.5 days. Of these men, 73% stayed less than 24 hours in hospital.4
  • Planning with MRI and biopsy: in focal treatment, the area to be treated is defined by MRI and by targeted or mapping biopsy.6
  • Limited reach: because the energy comes from the rectum, the front part of a large prostate is difficult to reach.1

HIFU can treat areas of different sizes:

ApproachWhat is treated
FocalOnly the areas with significant cancer6
Index lesionWhen there is more than one tumor, only the largest and highest-grade one, which may be responsible for progression5
Hemi-ablationThe half of the prostate where the cancer is, when it is on one side only8
Whole glandThe entire prostate, as a replacement for surgery or radiotherapy1,10

Who the studies included

Focal HIFU studies included men with cancer confined to the prostate, located by MRI and biopsy:

  • UK registry, 2018: 625 men with Gleason 6 to 9 and PSA up to 30 ng/mL. Gleason 6 was included only with at least 4 mm of cancer, and 84% had intermediate- or high-risk disease.6
  • HEAT registry, 2022: 1,379 men, with a median age of 66 years and a PSA of 6.9 ng/mL. By the D'Amico classification, 65% had intermediate-risk and 28% high-risk disease.7
  • French hemi-ablation study: 111 men with cancer on one side only, 68% low risk and 32% intermediate risk.8
  • US study of MRI-guided focused ultrasound: 101 men with ISUP grade group 2 or 3 disease, on one side only, visible on MRI and with PSA up to 20 ng/mL.16

The guidelines are stricter than these studies. The European guideline considers ablation of low-risk cancer highly likely to be overtreatment and does not recommend any form of ablation for high-risk disease.1 The American guideline says low-risk cancer should preferably be managed with active surveillance, and that ablation may be considered for intermediate-risk disease in selected, well-informed patients, with clinical trial enrollment prioritized.2 The pages on Gleason and ISUP and on high-risk disease explain these groups.

Results

The main studies of HIFU as a first treatment:

StudyWhoResult
Ahmed, 201241 men, focal HIFU95% with no cancer on MRI at 12 months, 4 of them after a second HIFU4
Ahmed, 201556 men with more than one tumor, only the index lesion treated81% with no significant cancer on biopsy at 12 months5
Rischmann, 2017111 men, hemi-ablation95% with no significant cancer on the treated side at 1 year; 89% free of radical treatment at 2 years8
Guillaumier, 2018625 men, focal HIFU, median follow-up of 56 months88% failure-free and 98% metastasis-free at 5 years6
Reddy, 20221,379 men, focal HIFU, 13 UK centers69% failure-free at 7 years: 68% for intermediate risk and 65% for high risk7
Crouzet, 20141,002 men, whole glandFree of PSA rise at 8 years: 76% for low risk, 63% for intermediate and 57% for high; 97% free of death from cancer at 10 years9
Ploussard, 20253,328 low- and intermediate-risk men, HIFU or prostatectomy, not randomizedHIFU not inferior for the need for further treatment at 30 months; median age 75 years with HIFU and 65 with surgery10

Two details help to read these numbers. In the UK studies, "failure-free" means not needing whole-gland or hormone treatment and having no metastasis or death from cancer. Repeat focal HIFU does not count as failure.7,8 And because part of the prostate remains, PSA falls but does not reach zero: in the 2015 study, the median lowest value was 2.4 ng/mL.5

Reviews summarize the evidence. A 2022 review gathered 27 studies of focal HIFU, with a median of 85% of men free of significant cancer in the treated area and 95% pad-free. Across the review, most studies were still at an early stage.11 A 2025 meta-analysis, with 20 groups treated with HIFU, found significant cancer on the control biopsy in 22.2% of men: 8.9% inside the treated area and 12.3% outside it. There was no difference between HIFU, cryotherapy and electroporation.12

Side effects

Side effects depend on the size of the treated area:

EffectFocal HIFU or hemi-ablationWhole-gland HIFU
Urine leakage2% used pads6; continence preserved in 97% after hemi-ablation810% to 12%1
ErectionsPreserved in 77% to 78% at one year6,9Erectile dysfunction in 23% to 61%1
Narrowing or obstruction9.6% needed a procedure through the urethra for urinary symptoms6Urethral stricture in 8%; urinary retention in 10%1
Fistula between the urethra and the rectum0.3% (2 of 625)60 to 5%1

A fistula is an abnormal connection between the urethra and the rectum. It is rare but serious: in the study of 625 men, one of the two cases healed with catheters for 6 months, and the other needed reconstructive surgery.6

With whole-gland HIFU, the technique improved over time. In the French series of 1,002 men, severe incontinence fell from 6.4% to 3.1%, and bladder outlet obstruction from 34.9% to 5.9%.9 In the French study comparing HIFU with prostatectomy, fewer men had worse continence at 12 months with HIFU (29% vs 44%), and the drop in erectile function was smaller. Urinary retention occurred in 10% after HIFU.10

The pages on continence and on erections and ejaculation explain these effects after prostatectomy.

Follow-up

Because part of the prostate stays in place, follow-up after HIFU differs from follow-up after surgery. The American guideline advises follow-up with PSA, digital rectal exam, MRI and biopsy, tailored to each patient's health and cancer.2 The European guideline notes that, after HIFU or cryotherapy, no PSA threshold has been validated as a sign that the cancer has come back.1 In the 2025 meta-analysis, 73.5% of the groups performed a control biopsy within the first 24 months.12

That is why MRI and fusion biopsy play a central role in follow-up.

If the cancer comes back

The cancer can come back in the treated area or appear in another part of the prostate.12 The literature describes three paths:

  • Repeat HIFU: in the HEAT registry, 252 of the 1,379 men had repeat focal HIFU.7 In that registry, the second session did not significantly worsen urinary or erectile function.1
  • Whole-gland treatment: the American guideline recommends offering prostatectomy or radiotherapy when salvage treatment is considered after focal therapy, with a biopsy first to confirm the recurrence.3 In the HEAT registry, 92 men needed whole-gland treatment.7
  • Salvage prostatectomy: in the series of 82 men who had robotic surgery after focal therapy, there were no intraoperative or major postoperative complications, and 83% were continent at one year. Progression-free survival was 74% at 12 months, 48% at 24 and 36% at 36. Recurrence inside the treated area and tumor in the seminal vesicles (pT3b) predicted worse results.15

The European guideline also cites a review of salvage radiotherapy after HIFU or cryotherapy, with a favorable side-effect profile and a PSA relapse rate of about 20%.1 The pages on robotic radical prostatectomy and radiotherapy explain each treatment.

HIFU after radiotherapy

When PSA rises after radiotherapy and scans show no metastases, the American guideline advises a prostate biopsy to confirm local recurrence before any salvage treatment.3 Once recurrence is confirmed, it recommends offering prostatectomy, cryoablation, HIFU or re-irradiation, through shared decision-making with the patient.3

Results of salvage HIFU:

  • Series of 418 men: free of PSA rise at 5 years in 58%, 51% and 36% of men with low, intermediate and high risk before radiotherapy. PSA before HIFU mattered a lot: 67% with PSA up to 4 ng/mL and 22% with PSA of 10 or more. With settings adapted to the irradiated prostate, incontinence fell from 32% to 19%, narrowing from 30% to 15% and fistula from 9% to 0.6%.13
  • French HIFI-2 study, 2026: 531 men, with a median age of 75 years. At 30 months, 71% had not needed hormone therapy. Severe incontinence rose from 7% before to 12% after HIFU.14
  • European guideline: pooling the studies, about 53% were free of PSA rise at 5 years, and severe urinary side effects reached about 23%. For this reason, it accepts salvage HIFU only in highly selected patients, in experienced centers and within studies.1

Ultrasound guided by MRI and through the urethra

Some forms of ultrasound ablation are done inside the MRI scanner, which measures temperature in real time:

  • MRI-guided focused ultrasound: in a US study of 101 men with ISUP grade group 2 or 3 disease, 88% had no grade group 2 or higher cancer in the treated area at 24 months. There was a single grade 3 adverse event, a urinary tract infection.16
  • TULSA (transurethral ultrasound ablation): the probe goes through the urethra, not the rectum, and the treatment spares the urethra and the sphincter. In the TACT study, with 115 men treated in the whole gland, 65% had no cancer on the 12-month biopsy, and erections were maintained or regained in 75%. Grade 3 adverse events occurred in 8%.17

Neither study had a comparison group with surgery or radiotherapy.17,18

Guidelines at a glance

SituationEuropean guideline (2026)American guidelines (AUA)
Low riskHighly likely to be overtreatment; only within trialsActive surveillance preferred
Intermediate riskFocal or whole-gland only within trials or registries (strong)Inform patients of the lack of high-quality comparative data (expert opinion)
High risk and locally advancedDo not offer (strong)For high risk, do not recommend outside a clinical trial (expert opinion)
Recurrence only in the prostate after radiotherapyHighly selected patients, with biopsy, within a trial (weak)One of the salvage options, with biopsy first (moderate)
Recurrence after focal therapyRepeat HIFU did not significantly worsen urinary or erectile function in the HEAT registryOffer prostatectomy or radiotherapy (expert opinion)

Sources: European guideline,1 American guideline on localized cancer2 and American salvage guideline.3

Second opinion

If you have been offered HIFU, as a first treatment or after radiotherapy, or you have had it and your PSA is rising again, a second opinion can be done entirely online, in English, with your test results sent in advance. The pages on surgery or radiotherapy, active surveillance and focal therapy help to compare the options.

Send your case

If you are considering HIFU, or have had it and have questions, and would like my opinion on your case before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.

Frequently asked questions

What is HIFU for prostate cancer?

It is high-intensity focused ultrasound. A probe placed in the rectum focuses ultrasound waves on one point of the prostate and heats the tissue above 65 °C, which destroys the cells by heat.1 HIFU can treat only the area of the tumor, half of the prostate or the whole gland.6,8,9

Is HIFU recommended as a first treatment?

With restrictions. The 2026 European guideline recommends offering HIFU, focal or whole-gland, for intermediate-risk disease only within clinical trials or registries, and not offering it for high-risk or locally advanced cancer.1 The American guideline asks that patients with intermediate-risk disease be told there is a lack of high-quality data comparing ablation with surgery, radiotherapy and active surveillance.2

Is HIFU as effective as surgery?

This is not known for certain, because there is no randomized trial. In a French study of 3,328 men, without randomization, HIFU was not inferior to prostatectomy for the need for further treatment at 30 months, but the men in the HIFU group were about ten years older.10 Systematic reviews conclude that long-term and comparative data are still lacking.11,12

Does HIFU cause erectile dysfunction or incontinence?

It can, less with focal treatment than with whole-gland treatment. In a study of 625 men treated with focal HIFU, 98% of those who returned questionnaires were pad-free.6 After hemi-ablation, erections were preserved in 78% of men at one year.8 For whole-gland HIFU, the European guideline reports incontinence in 10% to 12% and erectile dysfunction in 23% to 61%, depending on the series.1

Can prostate cancer come back after HIFU?

Yes. In the UK HEAT registry of 1,379 men, 252 had repeat focal HIFU for residual or recurrent cancer, and 92 needed whole-gland treatment. At 7 years, 69% were failure-free.7 When the cancer comes back, the literature describes repeating HIFU or treating the whole gland with surgery or radiotherapy.3,7

Can I have a prostatectomy after HIFU?

Yes. In the largest series of robotic prostatectomy after focal therapy, with 82 men, there were no major complications and 83% were continent at one year. Cancer control was worse when the cancer had come back in the treated area.15

Can HIFU be done after radiotherapy?

Yes, as salvage treatment, when a biopsy confirms that the cancer has come back only inside the prostate. The American guideline includes HIFU among the options, alongside surgery, cryotherapy and re-irradiation.3 The European guideline accepts it in highly selected patients, in experienced centers and within studies, because side effects are more frequent in this setting.1

References

  1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
  2. Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol. 2022;208(1):10-18. PubMed
  3. Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024;211(4):526-532. PubMed
  4. Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 2012;13(6):622-632. PubMed
  5. Ahmed HU, Dickinson L, Charman S, et al. Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study. Eur Urol. 2015;68(6):927-936. PubMed
  6. Guillaumier S, Peters M, Arya M, et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol. 2018;74(4):422-429. PubMed
  7. Reddy D, Peters M, Shah TT, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur Urol. 2022;81(4):407-413. PubMed
  8. Rischmann P, Gelet A, Riche B, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. Eur Urol. 2017;71(2):267-273. PubMed
  9. Crouzet S, Chapelon JY, Rouvière O, et al. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol. 2014;65(5):907-914. PubMed
  10. Ploussard G, Coloby P, Chevallier T, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. 2025;87(5):526-533. PubMed
  11. Hopstaken JS, Bomers JGR, Sedelaar MJP, et al. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol. 2022;81(1):5-33. PubMed
  12. Tay KJ, Fong KY, Stabile A, et al. Established focal therapy-HIFU, IRE, or cryotherapy-where are we now?-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2025;28(3):693-706. PubMed
  13. Crouzet S, Blana A, Murat FJ, et al. Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. BJU Int. 2017;119(6):896-904. PubMed
  14. Ploussard G, Coloby P, Chevallier T, et al. Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study). Eur Urol Oncol. 2026;9(5):1098-1105. PubMed
  15. Marconi L, Stonier T, Tourinho-Barbosa R, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol. 2019;76(1):27-30. PubMed
  16. Ehdaie B, Tempany CM, Holland F, et al. MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. Lancet Oncol. 2022;23(7):910-918. PubMed
  17. Klotz L, Pavlovich CP, Chin J, et al. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol. 2021;205(3):769-779. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation5.0186 Google reviews

Related guides